Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][9] Zacks Style Scores - Zacks Style Scores are indicators that help investors select stocks likely to outperform the market in the next 30 days, rated from A to F based on value, growth, and momentum [2] - The Value Score identifies attractive and discounted stocks using ratios like P/E and Price/Sales [3] - The Growth Score focuses on a company's financial health and future outlook, analyzing projected earnings and cash flow [4] - The Momentum Score capitalizes on price trends, using factors like weekly price changes to identify high-momentum stocks [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, outperforming the S&P 500 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [10] Teva Pharmaceutical Industries Ltd. - Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company based in Tel Aviv, Israel, focusing on branded and generic drugs, including biosimilars and OTC products [12] - Teva holds a Zacks Rank of 3 (Hold) with a VGM Score of A and a Momentum Style Score of B, having seen a 17.3% increase in shares over the past four weeks [13] - Recent upward revisions in earnings estimates for fiscal 2025 have increased the Zacks Consensus Estimate by $0.01 to $2.55 per share, with an average earnings surprise of 2.2% [13][14]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. is expected to report quarterly earnings of $0.47 per share, a decline of 2.1% year-over-year, with revenues projected at $3.97 billion, reflecting a 3.9% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 1.6% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts expect 'Revenue- COPAXONE- Total' to be $84.97 million, down 14.2% from the year-ago quarter [5]. - 'Revenue- API sales to third parties' is projected at $115.17 million, indicating a decrease of 10% year-over-year [5]. - 'Revenue- Other- Total' is estimated at $221.49 million, reflecting a significant decline of 30.4% from the previous year [5]. Geographic Revenue Insights - 'Geographic Revenue- International Markets' is expected to reach $615.76 million, a year-over-year increase of 3.1% [6]. - 'Geographic Revenue- United States' is projected at $1.87 billion, showing an 8.5% increase compared to the prior year [6]. - 'Geographic Revenue- United States- COPAXONE' is estimated at $32.38 million, up 7.9% from the year-ago quarter [6]. - 'Geographic Revenue- United States- BENDEKA / TREANDA' is forecasted to be $35.39 million, down 23.1% year-over-year [7]. - 'Geographic Revenue- United States- AUSTEDO' is expected to reach $360.74 million, reflecting a 27.9% increase from the previous year [7]. - 'Geographic Revenue- United States- Anda' is projected at $370.89 million, indicating a decrease of 2.7% year-over-year [8]. - 'Geographic Revenue- Europe- COPAXONE' is expected to be $43.68 million, down 23.4% from the year-ago quarter [8]. - 'Geographic Revenue- Europe- Respiratory products' is projected at $60.84 million, reflecting a decline of 7.8% year-over-year [9]. - 'Geographic Revenue- International Markets- Generic products' is expected to reach $487.47 million, indicating a 2.2% increase from the prior year [9]. Stock Performance - Over the past month, Teva shares have increased by 17.3%, outperforming the S&P 500 composite's 0.4% change [10]. - Teva holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [10].

Core Insights - Teva Pharmaceuticals and Alvotech announced FDA approval for SELARSDI™ (ustekinumab-aekn) as interchangeable with Stelara® (ustekinumab), effective April 30, 2025, for various conditions including psoriatic arthritis and Crohn's disease [1][7][8] Company Developments - The approval of SELARSDI is seen as a significant advancement for patient access to affordable treatment options, aligning with Teva's strategy to lead in the biosimilars market [2][4] - Teva has launched two biosimilars, SELARSDI and EPYSQLI, and has a robust pipeline of additional biosimilars expected to launch in the coming years [2][4] - Alvotech is expanding its portfolio with two approved biosimilars in the U.S. and three additional biosimilar candidates under FDA review, indicating a strong growth trajectory [2][6] Product Information - SELARSDI is available in multiple presentations, including 45 mg/0.5 mL and 90 mg/mL for subcutaneous injection, and 130 mg/26 mL for intravenous infusion [2][7] - The biosimilar targets the p40 protein, crucial for treating immune-mediated diseases, and is produced using the same cell line and process as Stelara® [3][7] Strategic Partnerships - Teva and Alvotech have a strategic partnership for the exclusive commercialization of biosimilars, which has been extended to include additional products and presentations [4][5] - The partnership allows Teva to leverage its extensive sales and marketing infrastructure while Alvotech manages development and manufacturing [4][5] Market Context - The approval of SELARSDI and other biosimilars is part of a broader trend towards increasing access to biologic treatments, which is essential for lowering healthcare costs [2][4] - The FDA's approval of SELARSDI as interchangeable with Stelara® is expected to enhance competition in the biologics market, benefiting patients and healthcare providers [2][4]

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positiveEPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S.Teva and Samsung Bioepis en ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options1These efforts underscore Teva's dedication to expanding access to innovative neurosci ...

PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very ...

Core Insights - Teva Pharmaceuticals presented a survey study on patient and healthcare professional attitudes towards TEV-'749, a long-acting injectable formulation of olanzapine, at the 2025 Congress of the Schizophrenia International Research Society, showing high satisfaction rates among patients and healthcare providers [1][2][4] Group 1: Survey Findings - Over 92% of schizophrenia patients reported satisfaction with TEV-'749's initiation regimen, dosing schedule, and trial medication [4][12] - 87% of nurses and 72% of physicians expressed satisfaction with TEV-'749 [1][12] - A significant preference for subcutaneous (78.6%) over intramuscular injection (21.4%) was noted among patients, with needle size being a primary factor [5] Group 2: Clinical Context - TEV-'749 is being evaluated in the Phase 3 SOLARIS trial, which aims to assess its efficacy, safety, and tolerability as a long-acting injectable for schizophrenia [11][9] - The drug leverages SteadyTeq™, a proprietary technology for controlled release, which may mitigate the risk of Post-Injection Delirium/Sedation Syndrome (PDSS) associated with current treatments [9][2] Group 3: Healthcare Professional Insights - Healthcare professionals indicated that the post-injection monitoring period could present barriers to treatment, with over 90% of physicians and more than 66% of nurses acknowledging potential challenges [5][12] - A majority of participants preferred a simpler initiation regimen requiring only one injection, with 72.9% of patients and 90.9% of physicians favoring this approach [5][12] Group 4: Broader Implications - Teva's commitment to advancing treatment for schizophrenia is underscored by the positive feedback from the survey, which highlights the importance of patient and provider perspectives in drug development [2][4] - The findings from the survey and ongoing trials may influence future treatment protocols and patient adherence strategies in schizophrenia management [3][4]

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call w ...

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the "Investors" page on its website. Q1 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. Going forward, it is Teva's intenti ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...